Summary & Overview
HCPCS Level II J9299: Injection, nivolumab, 1 mg
HCPCS Level II code J9299 denotes a 1 mg unit of nivolumab administered by injection, a monoclonal antibody therapy widely used across oncology indications. As a unit-based drug code for chemotherapy agents, J9299 is important for accurate drug reporting, inventory tracking, and payment processing in outpatient hospital settings nationwide. The code supports granular billing for weight- or dose-based regimens and for split-billing scenarios where partial vials or discarded amounts need separate documentation.
Major commercial payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will find a concise account of the clinical context for nivolumab as an oncology therapeutic, operational considerations for outpatient hospital billing, and common adjacent codes relevant to nivolumab product combinations. The publication summarizes typical sites of service and highlights areas where billing clarity is important, such as unit reporting and linkage to appropriate diagnosis codes.
This summary prepares billing specialists, hospital revenue staff, and policy analysts to interpret J9299 in claims workflows, reconcile service lines when unit-level chemotherapy drugs are billed, and understand which elements are present in the input data versus what is not provided. Data not available in the input is clearly identified in the body of the publication.
Billing Code Overview
HCPCS Level II code J9299 describes an injection of nivolumab, 1 mg. This entry represents a unit-based billing descriptor for the immunotherapeutic agent nivolumab used in oncology care. The service type is Chemotherapy Drugs and the typical site of service is Outpatient Hospital (POS 22).
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with metastatic melanoma presents to the outpatient hospital infusion center (POS 22) for administration of nivolumab. The oncology clinic schedules the visit after confirmatory imaging and oncology consultation documented malignant melanoma (ICD-10 C43.9) or another listed malignancy. The patient is evaluated by a medical or hematology-oncology physician, consented for immunotherapy, and screened for infusion safety (vitals, lab review including hepatic and renal function). Pharmacy verifies the ordered dose in milligrams and prepares nivolumab as a sterile injectable. Nursing performs pre-infusion checks, administers the drug intravenously, monitors for infusion reactions, and documents the exact milligram amount given. If any drug remains unused and is discarded, the dispenser documents waste and may append modifier JW on the claim. If a separate distinct procedural service occurs on the same day (for example a diagnostic infusion unrelated to the drug administration), modifier 59 may be reported with the drug administration line. Billing uses HCPCS Level II code J9299 to report nivolumab per 1 mg units for chemotherapy drug reimbursement in this outpatient hospital setting.
Coding Specifications
-
Modifier
JW: Drug amount discarded/not administered to any patient. Use when a portion of a single-use vial or prepared dose is discarded and the payer requires reporting of wasted drug units. -
Modifier
59: Distinct Procedural Service. Use when a service or procedure that is not normally reported together is performed on the same day as the infusion and meets the criteria for a distinct procedural service. -
Associated provider taxonomies and specialties:
| Taxonomy Code | Specialty |
|---|---|
207RH0003X | Hematology & Oncology Physician |
207RX0202X | Medical Oncology Physician |
207ZP0102X | Pediatric Hematology-Oncology Physician |
Related Diagnoses
-
C34.90— Malignant neoplasm of unspecified part of unspecified bronchus or lungClinical relevance: Primary or metastatic lung malignancy may be treated with immune checkpoint inhibitors such as nivolumab when clinically indicated.
-
C18.9— Malignant neoplasm of colon, unspecifiedClinical relevance: Advanced colorectal malignancies may be managed with systemic therapies; nivolumab may be used in select molecular contexts or clinical protocols.
-
C61— Malignant neoplasm of prostateClinical relevance: Prostate cancer is listed as a potential malignancy in the patient cohort; systemic immunotherapy use depends on tumor type and indication.
-
C25.9— Malignant neoplasm of pancreas, unspecifiedClinical relevance: Pancreatic cancer may be treated with systemic agents; nivolumab use would be based on tumor characteristics or clinical trial inclusion.
-
C43.9— Malignant melanoma of skin, unspecifiedClinical relevance: Melanoma is a common indication for immune checkpoint inhibitors like nivolumab and is a frequent clinical scenario for use of HCPCS Level II code
J9299.
Related Codes
| Code | Description |
|---|---|
J9298 | Injection, nivolumab and relatlimab‑rmbw, 3 mg/1 mg |
J9298is a combination immunotherapy product that includes both nivolumab and relatlimab‑rmbw. In clinical workflow,J9298is an alternative product when a combined formulation is indicated; it may be used instead of billing separate nivolumab units withJ9299. These codes are alternatives rather than additive, and the choice depends on the specific ordered product. Claims should reflect the actual drug administered and the appropriate HCPCS Level II code.
National Reimbursement Benchmarks
National mean rates for HCPCS Level II code J9299 vary substantially. BUCA (average commercial) mean rate of $173.30 is higher than Medicare (reported as $0.00 in the input), while Aetna’s mean rate of $656.40 is an outlier above both BUCA and Medicare.
Rate dispersion (P75 minus P25) is tightest for Cigna Health (33.00–33.00, range $0.00) and Blue Cross Blue Shield (33.00–35.00, range $2.00), and widest for Aetna (23.29–34.00, range $10.71). The table and chart below present the full breakdown of mean rates and percentiles for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.